Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
341-360 of 2,251 trials

Lumbar Spinal Surgery: Erector Spinae Plane Block

We are studying whether a specific pain management technique can reduce the need for morphine after lumbar spinal surgery. We will also look at recovery quality and any complications related to the procedure.

Patients Undergoing Lumbar ArthrodesisMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Urothelial Cancer: BT8009 Treatment Study

We are investigating whether the new drug BT8009, alone or with pembrolizumab, can help patients with advanced urothelial cancer live longer and respond better than standard chemotherapy.

Locally Advanced or Metastatic Urothelial Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: BI 764532 Treatment Study

We are testing different doses of BI 764532 in patients with relapsed small cell lung cancer and other neuroendocrine cancers. The goal is to see if this treatment can help improve outcomes for those who have not responded to prior therapies.

Small Cell Lung CancerNeuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Treatment Continuation Study

We are offering ongoing treatment for cancer patients who participated in earlier studies. This study checks the safety of the therapy while ensuring patients have access to their treatment.

Cancer Treatment Continuation>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Diabetic Foot Ulcers: Plasma Rich in Growth Factors Treatment

We are studying whether Plasma Rich in Growth Factors can help heal foot ulcers in diabetic patients better than standard treatments. This trial aims to improve healing outcomes for those with peripheral arterial disease.

Foot Ulcers in Diabetic Patients3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyEndocrinology

Pleural Mesothelioma: New Chemotherapy and Immunotherapy Study

We are exploring a new treatment combining chemotherapy and immunotherapy for patients with inoperable pleural mesothelioma. The study will evaluate treatment completion rates, side effects, and overall quality of life.

Inoperable Pleural Mesothelioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Non-Small Cell Lung Cancer: Zongertinib Study

We are testing whether zongertinib (BI 1810631) can improve outcomes for patients with advanced non-small cell lung cancer with HER2 mutations compared to standard treatment options.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Lower Respiratory Infections: Acyclovir Therapy

We are studying whether acyclovir can help ventilated patients with lower respiratory infections and herpes simplex virus. The trial aims to see if it improves survival and reduces hospital stays.

Pneumonia with Herpes Simplex Virus Infection6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Heart Disease Treatment: Drug-Coated Balloon vs. Drug-Eluting Stents

We are comparing a new balloon treatment with standard stents for patients with heart disease at high risk of bleeding. The goal is to see if the new method is just as effective while requiring less blood-thinning medication.

Coronary Artery Disease>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Non-ST Elevation Acute Coronary Syndrome: Aspirin Omission Study

We are investigating if avoiding aspirin can reduce bleeding risks for patients with non-ST segment elevation acute coronary syndrome. The goal is to see if this approach is as effective as current treatments for heart issues.

Non-ST-Segment Elevation Acute Coronary Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Advanced MTAP-null Solid Tumors: AMG 193 Treatment Study

We are studying the safety and effectiveness of AMG 193, both alone and with docetaxel, for adults with advanced MTAP-null solid tumors. This research aims to find better treatment options for these patients.

Advanced MTAP-null Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatologyOncology

CMV Prevention in Lung Transplant Recipients: Letermovir Study

We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.

Lung Transplant Patients (D+/R-)1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Hepatitis D: Bulevirtide Treatment Study

We are studying the effects of Bulevirtide in patients with chronic hepatitis D to see how well it reduces the virus and improves liver health. This research will help us understand the treatment's safety and effectiveness over time.

Hepatitis DConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology